Gene expression of estrogen receptor-alpha in orbital fibroblasts in Graves' ophthalmopathy

Arch Endocrinol Metab. 2015 Jun;59(3):273-6. doi: 10.1590/2359-3997000000050.

Abstract

Graves' ophthalmopathy (GO) is one of the most severe clinical manifestations of Graves' disease (GD), and its treatment might involve high-dose glucocorticoid therapy. The higher incidence of GO among females, and the reported association between polymorphisms of estrogen receptor (ER) and GD susceptibility have led us to question the role of estrogen and its receptor in GO pathogenesis. We, thus, assessed estrogen receptor-alpha (ERA) gene expression in cultures of orbital fibroblasts from a patient with GO before (controls) and after treatment with 10 nM and 100 nM dexamethasone (DEX). Orbital fibroblasts showed ERA gene expression. In the cells treated with 10 nM and 100 nM DEX, ERA gene expression was, respectively, 85% higher and 74% lower, than in the control group. We concluded that ERA gene expression is found in the orbital fibroblasts of patient with GO, which may be affected by glucocorticoids in a dose-related manner. Arch Endocrinol Metab. 2015;59(3):273-6.

Publication types

  • Case Reports

MeSH terms

  • Cells, Cultured
  • Dexamethasone / therapeutic use
  • Estrogen Receptor alpha / genetics*
  • Estrogen Receptor alpha / metabolism
  • Female
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Gene Expression* / drug effects
  • Glucocorticoids / therapeutic use
  • Graves Ophthalmopathy / drug therapy
  • Graves Ophthalmopathy / genetics*
  • Humans
  • Real-Time Polymerase Chain Reaction
  • Treatment Outcome

Substances

  • ESR1 protein, human
  • Estrogen Receptor alpha
  • Glucocorticoids
  • Dexamethasone